These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 18049471)

  • 1. The war against influenza: discovery and development of sialidase inhibitors.
    von Itzstein M
    Nat Rev Drug Discov; 2007 Dec; 6(12):967-74. PubMed ID: 18049471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-influenza drugs: the development of sialidase inhibitors.
    von Itzstein M; Thomson R
    Handb Exp Pharmacol; 2009; (189):111-54. PubMed ID: 19048199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitors and their role in avian and pandemic influenza.
    Crusat M; de Jong MD
    Antivir Ther; 2007; 12(4 Pt B):593-602. PubMed ID: 17944267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivirals and influenza: frequency of resistance.
    Monto AS
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral management of seasonal and pandemic influenza.
    Hayden FG; Pavia AT
    J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
    Du QS; Wang SQ; Chou KC
    Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuraminidase inhibitors in prophylaxis and treatment of influenza].
    Nitsch-Osuch A; Brydak LB; Wardyn AK
    Pol Merkur Lekarski; 2008 Jul; 25(145):67-73. PubMed ID: 18839619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
    Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
    J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.
    Haldar J; Chen J; Tumpey TM; Gubareva LV; Klibanov AM
    Biotechnol Lett; 2008 Mar; 30(3):475-9. PubMed ID: 17972018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial commentary: viral susceptibility and the choice of influenza antivirals.
    Monto AS
    Clin Infect Dis; 2008 Aug; 47(3):346-8. PubMed ID: 18582205
    [No Abstract]   [Full Text] [Related]  

  • 12. [Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].
    de Jong JC; Beyer WE; Rimmelzwaan GF; Fouchier RA; Osterhaus AD
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):73-9. PubMed ID: 14753128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999.
    Bauer K; Schrader C; Suess J; Wutzler P; Schmidtke M
    Antiviral Res; 2007 Sep; 75(3):219-26. PubMed ID: 17445913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
    Barr IG; Hurt AC; Iannello P; Tomasov C; Deed N; Komadina N
    Antiviral Res; 2007 Feb; 73(2):112-7. PubMed ID: 16963130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.
    Rameix-Welti MA; Agou F; Buchy P; Mardy S; Aubin JT; Véron M; van der Werf S; Naffakh N
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3809-15. PubMed ID: 16940075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005.
    Ferraris O; Kessler N; Valette M; Lina B
    Vaccine; 2006 Nov; 24(44-46):6656-9. PubMed ID: 16797804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
    Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of neuraminidase inhibitors to combat pandemic influenza.
    Democratis J; Pareek M; Stephenson I
    J Antimicrob Chemother; 2006 Nov; 58(5):911-5. PubMed ID: 16956904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of antiviral agents and other measures in an influenza pandemic.
    Groeneveld K; van der Noordaa J
    Neth J Med; 2005 Oct; 63(9):339-43. PubMed ID: 16244380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
    Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
    Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.